v3.26.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Schedule of Concentration, Percentage of Gross Revenues
The following table summarizes customers that represent 10% or greater of our consolidated total gross revenues:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Bayer (as described in Note 10)19.4%*10.9%20.5%
Customer A16.1%20.6%17.3%17.3%
Customer B19.1%22.5%23.4%17.1%
Customer C18.3%17.4%19.3%12.7%
Customer D12.2%17.4%13.1%12.9%
Customer E13.8%14.4%14.9%*
*Represents less than 10% and/or not a customer in the applicable period.
Total revenues, net is attributed to regions based on the location of our customers or license and collaboration partners.
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
U.S.71.7 %89.6 %82.9 %62.2 %
Europe, Middle East, and Africa (EMEA)27.6 %7.7 %16.3 %34.9 %
Asia-Pacific (APAC)0.7 %2.7 %0.8 %2.9 %
   Total100.0 %100.0 %100.0 %100.0 %
Schedule of Other Current Liabilities
Other current liabilities presented on the condensed consolidated balance sheets consisted of the following balances:
September 30, 2026December 31, 2025
(in thousands)
Accrued rebates and other related costs$92,937 $45,909 
Accrued commercial43,582 35,773 
Deferred royalty obligations, current portion (1)36,094 11,221 
Accrued cash dividends on preferred stock13,679 — 
Accrued interest5,043 14,411 
Accrued professional services8,938 3,665 
Other accrued liabilities11,841 9,243 
Total other current liabilities$212,114 $120,222 
(1)Including related party amounts of nil and $2,003 as of September 30, 2026 and December 31, 2025, respectively (as described in Note 9).
Schedule of Segment Information for Revenue, Significant Operating Expenses and Other Income (Expense), and Net Loss
The following table summarizes our segment information for significant operating expenses:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
(in thousands)(in thousands)
Revenues:
Net product revenue$253,346 $108,111 $656,382 $216,351 
License and services revenue79,314 8,311 89,537 125,441 
Royalty revenue20,511 4,278 45,443 6,106 
Total revenues, net353,171 120,700 791,362 347,898 
Operating costs and expenses:
Cost of revenues:
Cost of goods sold12,317 4,028 30,577 8,910 
Cost of license, services, and royalty revenue8,133 2,535 14,858 3,945 
Total cost of revenues20,450 6,563 45,435 12,855 
Research and development by significant program:
Acoramidis for the treatment of ATTR-CM and primary
   prevention in asymptomatic carriers of a pathogenic TTR variant		33,782 31,978 101,695 84,639 
Infigratinib for achondroplasia and hypochondroplasia34,089 30,756 105,082 88,881 
BBP-418 for LGMD2I/R924,971 14,253 67,232 39,705 
Encaleret for ADH127,048 16,046 71,555 44,633 
Other development programs3,292 357 16,815 22,323 
Other research programs20,324 19,484 57,211 55,355 
Total segment research and development143,506 112,874 419,590 335,536 
Selling, general and administrative200,854 137,621 551,011 373,140 
Restructuring, impairment, and related charges— 8,841 — 10,216 
Total operating costs and expenses364,810 265,899 1,016,036 731,747 
Loss from operations(11,639)(145,199)(224,674)(383,849)
Other income (expense), net:
Interest income13,105 6,239 26,010 15,522 
Interest expense(13,255)(11,739)(39,475)(41,467)
Noncash interest expense on deferred royalty obligations (1)(42,282)(36,410)(123,500)(86,460)
Net loss from equity method investments(7,312)(15,834)(32,030)(51,579)
Loss on extinguishment of debt— — — (21,155)
Other income, net2,116 16,461 11,956 31,240 
Total other expense, net(47,628)(41,283)(157,039)(153,899)
Loss before income taxes(59,267)(186,482)(381,713)(537,748)
Provision for (benefit from) income taxes1,229 (1,545)1,229 555 
Net loss(60,496)(184,937)(382,942)(538,303)
Net loss attributable to redeemable convertible noncontrolling
   interests and noncontrolling interests		3,786 2,194 9,973 6,235 
Net loss attributable to BridgeBio(56,710)(182,743)(372,969)(532,068)
Preferred stock dividends and accretion26,293 — 26,293 — 
Segment net loss attributable to common stockholders of BridgeBio$(83,003)$(182,743)$(399,262)$(532,068)
(1)Including related party amounts of $(2,942) and $(13,878) for the period from July 1, 2026 to August 16, 2026 and for the period from January 1, 2026 to August 16, 2026, respectively, and $(5,383) and $(5,560) for the three and nine months ended September 30, 2025, respectively (as described in Note 9).
Schedule of Inventories Presented on Condensed Consolidated Balance Sheet
Inventories presented on the condensed consolidated balance sheets consisted of the following balances:
September 30, 2026December 31, 2025
(in thousands)
Raw materials$30,003 $14,997 
Work in process16,025 6,104 
Finished goods17,641 6,509 
Inventory reserve(3,951)(857)
   Total inventories$59,718 $26,753